Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes."

Following an fantabulous tally successful June, erstwhile the banal roseate by much than 19%, Viking Therapeutics (NASDAQ: VKTX) banal precocious dipped, perchance creating a buying accidental for an breathtaking maturation banal with immense imaginable successful the weight-loss cause sector. Is the dip capable to marque the banal a buy?

Wall Street loves Viking Therapeutics

According to Visible Alpha, the Wall Street statement terms people for the banal is conscionable beneath $91, representing a imaginable 150% instrumentality from the existent price. The analyst's excitement astir the banal stems from its pb cause candidate, VK2735, and its imaginable successful the highly lucrative weight-loss market.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

VK2735 is being developed arsenic a dual formulation therapy, whereby, for example, it tin beryllium initially taken by injection (subcutaneously) and aboriginal successful oral signifier arsenic a attraction dose oregon to proceed value loss. Investors are besides hoping the promising efficacy information (VK2735 appears to person a steeper velocity of value nonaccomplishment than rival drugs) from the signifier 2 trials (oral and subcutaneous) volition beryllium repeated successful signifier 3 trials. The subcutaneous signifier 3 proceedings is successful progress, portion the oral signifier 3 proceedings volition statesman successful the 4th fourth of this year.

Is it a banal to buy?

VK2735 is simply a imaginable crippled changer for the company, but risks remain, not slightest owed to immoderate questionable tolerability information from the signifier 2 oral trial. Moreover, the signifier 3 results from the subcutaneous VK2735 proceedings won't beryllium disposable until precocious 2027 astatine the earliest, and the oral 2735 signifier 3 results aren't owed until 2028.

That said, determination is simply a signifier 1 attraction dosing proceedings (participants volition instrumentality subcutaneous VK2735 for 19 weeks earlier switching to a scope of subcutaneous and oral attraction doses) successful progress, with results from the subcutaneous play owed successful the existent 4th and the oral attraction results owed successful the archetypal fractional of 2027.

Wall Street says "buy," but cautious investors whitethorn privation to hold to show the attraction proceedings results earlier buying in, arsenic the signifier 3 results won't travel retired for a while.

Should you bargain banal successful Viking Therapeutics close now?

Before you bargain banal successful Viking Therapeutics, see this:

The Motley Fool Stock Advisor expert squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and Viking Therapeutics wasn't 1 of them. The 10 stocks that made the chopped could nutrient monster returns successful the coming years.